Cue Biopharma, INC 10-Q quarterly reports

Cue Biopharma's Q1 2026 report details significant collaboration revenue growth and strategic advancements in its drug candidate pipeline, alongside ongoing efforts to secure future funding.

Cue Biopharma reports Q3 2025 results, highlighting a net loss of $7.4 million, reduced R&D expenses, and new collaborations while facing substantial doubt about its ability to continue as a going concern.

Cue Biopharma reported a reduced net loss and secured a significant collaboration with Boehringer Ingelheim, but faces substantial doubt about its ability to continue as a going concern and a Nasdaq minimum bid deficiency.

Cue Biopharma announces its Q1 2025 financial results, emphasizing a new collaboration with Boehringer Ingelheim and ongoing efforts to secure additional funding amidst going concern uncertainties.

Cue Biopharma announced its third quarter 2024 results, highlighting a strategic shift towards autoimmune programs while continuing to monitor oncology assets.

Cue Biopharma shifts focus to autoimmune programs while reporting a net loss of $22.5 million for the first half of 2024, alongside ongoing clinical trial progress.

Cue Biopharma's Q1 2024 report highlights ongoing clinical trials for its cancer therapies and advancements in autoimmune disease programs, while acknowledging the need for additional funding.